Notice: Get a jump on 2015 — Pay your 2015 ASA membership dues now!

>

MEETINGS / EVENTS

RSS

January 23 - 25 2015, 12:00 AM - 12:00 AM

ASA PRACTICE MANAGEMENT 2015

February 07 - 08 2015, 12:00 AM - 12:00 AM

ASA Certificate in Business Administration 2015

June 26 - 28 2015, 12:00 AM - 12:00 AM

Annual Perioperative Surgical Home Summit

>

FDA MEDWATCH ALERTS

December 18, 2014

0.9 Percent Sodium Chloride Injection USP in 100 mL MINI-BAG PLUS Container by Baxter: Recall - Particulate Matter

Summary:

FDA MedWatch Recall - Particulate Matter

November 21, 2014

FDA MedWatch - Respironics California, Esprit V1000 and V200 Ventilators: Class I Recall - Power Failure May Occur

Summary:

FDA MedWatch Respironics California Esprit V1000 and V200 Ventilators Class I Recall

November 21, 2014

FDA MedWatch - Highly Concentrated Potassium Chloride Injection, 10 mEq per 100 mL by Baxter: Recall - Mislabeled

Summary:

Highly Concentrated Potassium Chloride Injection 10 mEq per 100 mL by Baxter Recall Mislabeled

>

ASA FEATURED PRODUCT

Add this product to your shopping cart

Self-Education and Evaluation (SEE) Program

SKU: 30701-14CE

... Read more »

Single Copies, Member Price: $360

ASA Submits Testimony and Solutions on Drug Shortages to Congress

Wednesday, December 21, 2011

Continuing our call for strong legislative action, ASA offered the perspective of anesthesiologists and solutions to the growing drug shortage pandemic in an official submission to the U.S. Senate Finance and U.S. Senate Health, Education, Labor and Pension (HELP) Committees.  Among other items, ASA highlighted the dramatic impact of drug shortages on anesthesiologists and our patients as indicated in the ASA drug shortage survey, and urged immediate action by highlighting recommendations offered by the ASA co-convened Drug Shortage Summit Steering Group.  
 
Over the course of the last two years, ASA has actively led efforts to combat the drug shortage issue on both the legislative and regulatory fronts.  Some of the most recent government actions on this important topic include the Food and Drug Administration (FDA) interim final rule mandating additional manufacturer notification requirements related to drug shortages and a long-awaited Government Accountability Office report on drug shortages in which anesthesia drug shortages were identified as the class of drugs with the highest frequency of shortages (23 percent of all drug shortages during the last two years).
  
Review ASA’ official submission to the Senate Finance Committee and review ASA’ submission to the Senate Health, Education, Labor and Pension Committee.

Learn more about ASA's work on the drug shortage issue.

« Back to Washington Alerts